Table 5 Characteristics and outcomes of patients treated for hepatitis C in the HIV primary care model dichotomized according to risk category based on assigned HCV treatment monitoring group*
From: Increasing Hepatitis C treatment uptake among HIV-infected patients using an HIV primary care model
Clinic model | High-risk | Non-high-risk | P value |
|---|---|---|---|
(n = 17) | (n = 31) | ||
Median age - years (range) | 49 (19–61) | 47 ( 33–61) | 0.77a |
Sex: Male (%) | 14 (82) | 24 (77) | 0.68b |
Race | |||
White | 13 | 19 | 0.14c |
Black | 2 | 11 | |
Other/unknown | 2 | 1 | |
Ethnicity | |||
Hispanic | 2 | 5 | 0.68c |
Not-Hispanic | 15 | 26 | |
Median T CD4+ cell count - cells/mm3 (range) | 515(130–1136) | 529(170–1140) | 0.55a |
Number with undetectable HIV load (%) | 14 (82) | 26 (84) | 0.91b |
Hepatitis C genotype | |||
Genotype 1/4 | 13 | 26 | 0.53b |
Genotype 2/3 | 4 | 5 | |
Median HCV load - log10 copies/mL (range) | 6.44(4.05–7.46) | 6.40(3.0–7.6) | 0.73a |
Liver biopsy scores 1 | |||
F0-2 | 4 | 8 | 0.51c |
F3,4 | 6 | 7 | |
Median Hemoglobin levels - g/dL (range) | 14.5(12.9–15.8) | 14.4(12.1–16.6) | 0.63a |
Median Platelet count -1000/mm3 (range) | 191(113–418) | 227(119–402) | 0.38a |
Median ALT - U/L (range) | 85(22–301) | 56(19–1087) | 0.08a |
HCV treatment outcomes | |||
№ Patients with Sustained viral response (%) | 5(29) | 16(52) | 0.14b |
№ Patients who discontinued HCV therapy due to non-viral response (%) | 2(12) | 7(23) | 0.36b |
№ Patients who discontinued HCV therapy due to treatment-related side effects (%) | 6(35) | 8(26) | 0.49b |
№ Patients lost to follow-up (%) | 3(18) | 1(3) | 0.08b |